BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced that the Company exhibited the MicroThermX® Microwave Ablation System at the World Conference on Interventional Oncology (WCIO) meeting, which was held June 9 to June 12, 2010, in Philadelphia, Pennsylvania.
BSD has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA) for premarket clearance of the Company's MicroThermX® Microwave Ablation System (MTX) for ablation of soft tissue. The 510(k) clearance is pending. Clearance from the FDA of BSD Medical's 510(k) Premarket Notification submission will authorize the commercial sale of the MTX in the United States.
The MTX was designed to provide an optimized system that is targeted to the growing therapeutic interventional oncology market. The interventional oncology worldwide market for 2009 was estimated at $210 million, and this market is projected to grow to $480 million by 2015.
Cetuximab performs better than durvalumab in treating head and neck cancers